Aratana Gets Rights To Two Compounds For Animal Use

Posted: March 4, 2011, 5:25 p.m., EDT



Published:

Aratana Therapeutics Inc. of Kansas City, Kan., reported today that it has entered into a license agreement with RaQualia Pharma Inc. to develop two compounds from RaQualia’s human clinical development portfolio for companion animal use.

As part of the agreement, Aratana will be granted global rights for development and commercialization of the licensed animal health products. In exchange, the Japanese company will receive upfront payment, development milestones and royalties on global sales.

The first compound is a selective EP-4 antagonist. Aratana reported that the compound has achieved proof of efficacy in human studies and has demonstrated efficacy in animal models for several conditions including, pain, cancer and autoimmune/inflammatory diseases.

The second compound, a selective Ghrelin agonist, has achieved proof of efficacy in human studies and has demonstrated efficacy in animal models for treatment of cachexia and frailty, according to Aratana.

Aratana announced its entry into the animal health industry in early January, which was jump-started by $20 million in Series A financing.


Related story: Aratana Enters Animal Health Industry with $20 Million in Funding

 

 

<Home>

Edit Module
Edit ModuleShow Tags

Archive »Read More

Wildlife, Exotic Animal Medicine Symposium to be Held in April

The symposium will be held at the University of California, Davis.

Interceptor Heartworm Drug Returns Under Elanco

Discontinued by Novartis, Interceptor should be available this spring under new owner Elanco.

Idexx Unveils Kidney Test Breakthrough

A test being added to Idexx profiles may identify the onset of kidney disease about 17 months sooner in cats and dogs.

Add your comment:
Edit Module
Edit ModuleEdit ModuleShow Tags Edit Module
Edit Module Edit Module
Edit ModuleShow Tags

Events


Show More...
Edit Module
Edit Module